Table 2.
DRQOL scores during maintenance therapy
| DRQOL questionnaire | Change from baseline to cycle 6 (maintenance) |
Treatment arm | Baseline (maintenance) |
Mean difference at cycle 6 (maintenance) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (N) | Mean difference | 95% CI (lower, upper) | Two-sided P value | Patients (N) | Mean score | Std. deviation | Std. error mean | Two-sided P value | Patients (N) | Mean difference | 95% CI (lower, upper) | Two-sided P value | ||||
| Skindex-16 | 131.00 | −14.84 | −19.82 | −9.86 | 0.000 | FU/FA+Pmab | 106.00 | 28.15 | 26.11 | 2.54 | 0.962 | 66.00 | −16.53 | −22.68 | −10.38 | 0.000 |
| FU/FA | 92.00 | 28.33 | 26.48 | 2.76 | 65.00 | |||||||||||
| Skindex-16: Symptom | 131.00 | −17.78 | −23.55 | −12.01 | 0.000 | FU/FA+Pmab | 106.00 | 33.77 | 28.20 | 2.74 | 0.919 | 66.00 | −19.54 | −26.98 | −12.09 | 0.000 |
| FU/FA | 92.00 | 34.19 | 30.74 | 3.20 | 65.00 | |||||||||||
| Skindex-16: Emotional | 131.00 | −15.96 | −21.27 | −10.65 | 0.000 | FU/FA+Pmab | 106.00 | 29.35 | 28.63 | 2.78 | 0.873 | 66.00 | −17.22 | −23.67 | −10.77 | 0.000 |
| FU/FA | 92.00 | 29.99 | 28.25 | 2.94 | 65.00 | |||||||||||
| Skindex-16: Functional | 131.00 | −10.77 | −15.64 | −5.90 | 0.000 | FU/FA+Pmab | 106.00 | 21.58 | 25.62 | 2.50 | 0.988 | 66.00 | −13.18 | −19.37 | −7.00 | 0.000 |
| FU/FA | 92.00 | 21.52 | 26.08 | 2.72 | 65.00 | |||||||||||
| DLQI | 129.00 | −2.77 | −3.87 | −1.66 | 0.000 | FU/FA+Pmab | 103.00 | 5.87 | 5.91 | 0.58 | 0.933 | 67.00 | −3.53 | −4.86 | −2.20 | 0.000 |
| FU/FA | 90.00 | 5.94 | 5.69 | 0.60 | 62.00 | |||||||||||
| FACT-EGFRI | 120.00 | 7.32 | 4.28 | 10.36 | 0.000 | FU/FA+Pmab | 88.00 | 53.76 | 13.20 | 1.41 | 0.875 | 60.00 | 11.39 | 7.57 | 15.21 | 0.000 |
| FU/FA | 80.00 | 54.11 | 15.30 | 1.71 | 60.00 | |||||||||||
First panel: mean changes in DRQOL scores from baseline to cycle 6 of maintenance therapy. Second panel: mean DRQOL scores at baseline by treatment arm (bold: FU/FA + Pmab arm). Third panel: mean differences in DRQOL scores at cycle 6 of maintenance therapy between the two treatment arms (FU/FA + Pmab versus FU/FA).
CI, confidence interval; DLQI, Dermatology Life Quality Index; DRQOL, dermatology-related quality of life; FACT-EGFRI, Functional Assessment of Cancer Therapy-epidermal growth factor receptor inhibitor; FU/FA, fluorouracil, folinic acid; Pmab, Panitumumab.